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Abstract
To define the cell populations that drive joint inflammation in rheumatoid arthritis (RA), we 
applied single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA-seq and flow 
cytometry to T cells, B cells, monocytes and fibroblasts from 51 samples of synovial tissue from 
patients with RA or osteoarthritis. Utilizing an integrated strategy based on canonical correlation 
analysis of 5,265 scRNA-seq profiles, we identified 18 unique cell populations. Combining mass 
cytometry and transcriptomics together revealed cell states expanded in RA synovia: 
THY1(CD90)+HLA-DRAhi sublining fibroblasts, IL1B+ pro-inflammatory monocytes, ITGAX
+TBX21+ autoimmune-associated B cells and PDCD1+ T peripheral helper (Tph) and T follicular 
helper (Tfh). We defined distinct subsets of CD8+ T cells characterized by a GZMK+, GZMB+ and 
GNLY+ phenotype. We mapped inflammatory mediators to their source cell populations; for 
example, we attributed IL6 expression to THY1+HLA-DRAhi fibroblasts, and IL1B production to 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondence and requests for materials should be addressed to Soumya Raychaudhuri, 77 Avenue Louis Pasteur, Harvard New 
Research Building, Suite 250D, Boston, MA 02446, USA. soumya@broadinstitute.org; 617-525-4484 (tel); 617-525-4488 (fax).
AUTHOR CONTRIBUTIONS
S.K., S.M.G., D.T., L.B.H., K.S.-E., A.M.M., D.L.B., J.H.A., V.P.B., V.M.H., A.F., C.P., H.P., G.S.F., L.M., P.K.G., W.A. and L.T.D. 
recruited patients and obtained synovial tissues. B.F.B., E.D. and E.M.G. performed histological assessment of tissues. K.W., D.A.R., 
G.F.M.W., and M.B.B. designed and implemented tissue processing and cell sorting pipeline. J.A.L. obtained mass cytometry data 
from samples. N.H., C.N., and T.M.E. obtained single cell RNA-seq data from samples. F.Z., K.S., C.Y.F., D.J.L. and S.R. conducted 
computational and statistical analysis. A.H.J., J.R.-M., N.M.P., and C.R., designed and performed validation experiments. K.S., F.Z., 
and J.R.M. implemented the website. J.A., S.L.B., C.D.B., J.H.B., J.D., J.M.G., M.G., L.B.I., E.A.J., J.A.J., J.K., Y.C.L., M.J.M., 
M.M., F.M., J.N., A.N., D.E.O., M.P., C.R., W.H.R., A.S., D.S., J.S., J.D.T., and P.J.U. contributed to the procurement and processing 
of samples, design of the AMP study. S.R., M.B.B., J.H.A., and L.T.D. supervised the research. F.Z., K.W., K.S, and S.R. generated 
figures and wrote the initial draft. K.S, C.Y.F. D.A.R, L.T.D., J.H.A, M.B.B. edited the draft, and all the authors participated in writing 
the final manuscript.
^Co-first authors
*Co-senior authors
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data Availability
The single-cell RNA-seq data, bulk RNA-seq data, mass cytometry data, flow cytometry data, and the clinical and histological data 
this study are available at ImmPort (https://www.immport.org/shared/study/SDY998 and https://www.immport.org/shared/study/
SDY999, study accession codes SDY998 and SDY999). The raw single-cell RNA-seq and mass cytometry data are deposited in 
dbGAP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001457.v1.p1. The source code repository of the 
computational and statistical analysis is located athttps://github.com/immunogenomics/amp_phase1_ra. Data can also be viewed on 3 
different websites at https://immunogenomics.io/ampra, https://immunogenomics.io/cellbrowser/, and https://
portals.broadinstitute.org/single_cell/study/amp-phase-1.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
HHS Public Access
Author manuscript
Nat Immunol. Author manuscript; available in PMC 2019 November 06.
Published in final edited form as:
Nat Immunol. 2019 July ; 20(7): 928–942. doi:10.1038/s41590-019-0378-1.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pro-inflammatory monocytes. These populations are potentially key mediators of RA 
pathogenesis.
Rheumatoid arthritis (RA) is an autoimmune disease with chronic inflammation in the 
synovium of the joint tissue1–3. This inflammation leads to joint destruction, disability and 
shortened life span4. Defining key cellular subsets and their activation states in the inflamed 
tissue is a critical step to define new therapeutic targets for RA. CD4+ T cell5,6 B cells7, 
monocytes8,9, and fibroblasts10,11 have established relevance to RA pathogenesis. Here, we 
use single cell technologies to view all of these cell types simultaneously across a large 
collection of samples from inflamed joints. We believe a global single-cell portrait of how 
different cell types work together would advance our understanding of therapeutics.
Application of transcriptomic and cellular profiling technologies to whole synovial tissue 
has already identified specific cell populations associated with RA3,12–14. However, most 
studies have focused on a pre-selected cell type, surveyed whole tissues rather than 
disaggregated cells, or used only a single technology platform. The latest advances in single-
cell technologies offer an opportunity to identify disease-associated cell subsets in human 
tissues at high resolution in an unbiased fashion15–17. These technologies have already been 
used to discover roles for T peripheral helper (Tph) cells18 and HLA-DR+CD27− cytotoxic 
T cells19 in RA pathogenesis. Studies using scRNA-seq have defined myeloid cell 
heterogeneity in human blood20 and identified overabundance of PDPN+CD34−THY1+ 
(THY1, also known as CD90) fibroblasts in RA synovial tissue15,21.
To generate high-dimensional multi-modal single-cell data from synovial tissue samples 
collected across a collaborative network of research sites, we developed a robust pipeline22 
in the Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus (AMP RA/SLE) 
consortium. We collected and disaggregated tissue samples from patients with RA and 
osteoarthritis (OA), and then subjected constituent cells to scRNA-seq, sorted-population 
bulk RNA-seq, mass cytometry, and flow cytometry. We developed a unique computational 
strategy based on canonical correlation analysis (CCA) to integrate multi-modal 
transcriptomic and proteomic profiles at a single cell level. A unified analysis of single cells 
across data modalities can precisely define contributions of specific cell subsets to pathways 
relevant to RA and chronic inflammation.
RESULTS
Generation of parallel mass cytometric and transcriptomic data from synovial tissue
In phase 1 of AMP RA/SLE, we recruited 36 patients with RA that met the 1987 American 
College of Rheumatology (ACR) classification criteria and 15 patients with OA from 10 
clinical sites over 16 months (Supplementary Table 1) and obtained synovial tissues from 
ultrasound-guided biopsies or joint replacements (Methods, Fig. 1a). We required that all 
tissue samples included had synovial lining documented by histology. Synovial tissue 
disaggregation yielded an abundance of viable cells for downstream analyses (362,190 +/
− 7,687 (mean +/− SEM) cells per tissue). We used our validated strategy for cell sorting22 
(Fig. 1a) to isolate B cells (CD45+CD3−CD19+), T cells (CD45+CD3+), monocytes 
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(CD45+CD14+), and stromal fibroblasts (CD45−CD31−PDPN+) (Supplementary Fig. 1a). 
We applied bulk RNA-seq to all four sorted subsets for all 51 samples. For samples with 
sufficient cell yield (Methods), we also measured single-cell protein expression using a 34-
marker mass cytometry panel (n=26, Supplementary Table 2), and single-cell RNA 
expression in sorted cell populations (n=21, Fig. 1b).
Summary of computational data integration strategy to define cell populations
To confidently define RA-associated cell populations, we integrated multiple data modalities 
(Fig. 1b, c). We use bulk RNA-seq data as the reference point because it was available for all 
of the donors and most of the cell types, it had the highest dimensionality and least sensitive 
to technical artifacts (Fig. 1b).
Integrating scRNA-seq with bulk RNA-seq data ensures robust discovery of cell populations. 
Here, we used CCA to find linear combinations of bulk RNA-seq samples and scRNA-seq 
cells (Fig. 1c, d) to create gene expression profiles that were maximally correlated. These 
linear combinations captured sources of shared variation between the two datasets and 
allowed us to identify individual cell populations that drive variation in the bulk RNA-seq 
data. We analyzed the scRNA-seq data by using the canonical variate coefficients for each 
cell to compute a nearest neighbor network, identifying clusters with a community detection 
algorithm, and evaluating the separation between clusters with Silhouette analysis (Methods, 
Supplementary Fig. 2b).
We identified cell clusters in mass cytometry data with density-based clustering23. Next, we 
used CCA to identify linear combinations of bulk RNA-seq genes and mass cytometry 
cluster abundances that maximize correlation across patients. These canonical variates offer 
a way to visualize genes and mass cytometry clusters together. We then queried this CCA 
result with the best marker genes from scRNA-seq to establish a relationship between each 
scRNA-seq cluster and each mass cytometry cluster (Methods). We also used CCA to 
associate bulk gene expression in each sample with proportions of cells in different flow 
cytometry gates.
Flow cytometry features define a set of RA synovia that are leukocyte-rich
Histology of RA synovial tissues revealed heterogeneous tissue composition with variable 
lymphocyte and monocyte infiltration (Fig. 2a,b, Supplementary Fig. 2c,d). This 
heterogeneity was expected, because variation in tissue immune cell infiltration reflects local 
disease activity in the source joint. Consequently, we employed a data-driven approach to 
separate samples based on flow cytometry of lymphocyte and monocyte infiltration in each 
tissue sample (Supplementary Fig. 1b,c). We calculated a multivariate normal distribution of 
these parameters based on OA samples as a reference, and for each RA sample we 
calculated the Mahalanobis distance from OA24. We defined the maximum OA distance 
(4.5) as the threshold for defining leukocyte-rich RA (>4.5, n=19) or leukocyte-poor RA 
(<4.5, n=17) samples (Methods, Supplementary Fig. 1d). Whereas leukocyte-rich RA tissues 
had significant infiltration of synovial T cells and B cells, leukocyte-poor RA tissues had 
cellular compositions more similar to OA (Fig. 2c). Synovial monocyte abundances were 
similar between RA and OA (Fig. 2c).
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To test if our classification indicates inflammation, we assessed tissue histology and 
assigned each sample a Krenn inflammation score25. Samples we classified as leukocyte-
rich RA had a significantly higher Krenn inflammation score than leukocyte-poor RA or OA 
(Fig. 2d). In contrast, synovial lining membrane hyperplasia was not significantly different 
between leukocyte-rich RA, leukocyte-poor RA, and OA samples (Fig. 2d). We observed 
significant correlation between synovial leukocyte infiltration measured by flow cytometry 
and the histological Krenn inflammation score (Fig. 2e). Mass cytometry in 26 synovial 
tissues was consistent with flow cytometry and histology. OA and leukocyte-poor RA 
samples were characterized by high abundance of fibroblasts and endothelial cells; while 
leukocyte-rich RA tissues were characterized by high abundance of CD4 T, CD8 T, and B 
cells (Fig. 2f, Supplementary Fig. 3a).
Single-cell RNA-seq analysis reveals distinct cell subpopulations
Next, we analyzed 5,265 scRNA-seq profiles passing quality control (Methods), including 
1,142 B cells, 1,844 fibroblasts, 750 monocytes, and 1,529 T cells. We used canonical 
variates (from CCA with bulk RNA-seq) to define 18 cell clusters that were independent of 
donor (n=21) and technical plate (n=24) effects (Fig. 3a–bb, Supplementary Fig. 2c, 
Supplementary 4a). In contrast, conventional PCA-based clustering led to clusters that were 
confounded by batch effects (Supplementary Fig. 4b). All of the clusters in the PCA-based 
clustering, excluding clusters confounded by batch, were identified in CCA-based 
clustering. Next, we compared expression values between cells in the cluster and all other 
cells to select cluster marker genes (Methods, Supplementary Table 4). For selected genes, 
we show expression values in each cell positioned in a t-distributed Stochastic Neighbor 
Embedding (tSNE26) (Fig. 3c–f). Among fibroblasts, we identified four putative 
subpopulations (Fig. 3c): CD34+ sublining fibroblasts (SC-F1), HLA-DRAhi sublining 
fibroblasts (SC-F2), DKK3+ sublining fibroblasts (SC-F3), and CD55+ lining fibroblasts 
(SC-F4). In monocytes (Fig. 3d), we identified IL1B+ pro-inflammatory monocytes (SC-
M1), NUPR1+ monocytes (SC-M2), C1QA+ monocytes (SC-M3), and interferon (IFN) 
activated monocytes (SC-M4). In T cells (Fig. 3e), we identified three CD4+ clusters: 
CCR7+ T cells (SC-T1), FOXP3+ regulatory T cells (Treg cells) (SC-T2), and PDCD1+ Tph 
and T follicular helper (Tfh) (SC-T3); and three CD8+ clusters: GZMK+ T cells (SC-T4), 
GNLY+GZMB+ cytotoxic lymphocytes (CTLs) (SC-T5), and GZMK+GZMB+ T cells (SC-
T6). Within B cells (Fig. 3f), we identified four cell clusters, including naive IGHD+CD27− 
(SC-B1) and IGHG3+CD27+ memory B cells (SC-B2). We identified an autoimmune-
associated B cells (ABCs) cluster (SC-B3) with high expression of ITGAX (also known as 
CD11c) and a plasmablast cluster (SC-B4) with high expression of immunoglobulin genes 
and XBP1, a transcription factor for plasma cell differentiation27.
We assessed protein fluorescence measurements of typical cell type markers, which were 
consistent with our identified scRNA-seq clusters (Supplementary Fig. 2e). Cell density 
quantified from 10 histology samples was correlated with the lymphocyte flow cytometric 
cell yields, suggesting that samples with the most single cell measurements are those with 
the best yields and the most inflammation (Supplementary Fig. 5).
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Distinct synovial fibroblasts defined by cytokine activation and MHC II expression
To identify the fibroblast subpopulations overabundant in leukocyte-rich RA synovia, we 
selected marker genes for each cluster and assessed their expression levels in bulk RNA-seq 
from sorted fibroblasts (CD45−PDPN+) from RA and OA patients. For example, genes 
associated with HLA-DRAhi (SC-F2) fibroblasts were more highly expressed in bulk RNA-
seq samples from leukocyte-rich RA than OA (t-test p<1×10−3 for HLA-DRA, IFI30, and 
IL6) (Fig. 4a). Since the expression profile of a bulk tissue sample is an aggregate of the 
expression profiles of its constituent cell populations, this result suggests expansion of HLA-
DRAhi (SC-F2) fibroblasts in RA tissues. Genes associated with CD55+ fibroblasts (SC-F4) 
were significantly more highly expressed in bulk RNA-seq samples from OA than 
leukocyte-rich RA (t-test p<1×10−3 for HBEGF, CLIC5, HTRA4, and DNASE1L3) (Fig. 
4a). CD55+ fibroblasts (SC-F4) were the most transcriptionally distinct subset from the three 
THY1+ clusters (SC-F1–3), including the highest expression of lubricin (PRG4), suggesting 
that these cells represent synovial lining fibroblasts and THY1+ fibroblasts (SC-F1–3) 
represent sublining (Fig. 4a). Next, we use the averaged expression level of the best marker 
genes for each scRNA-seq cluster (AUC>0.7) and tested for differential expression in bulk 
RNA-seq fibroblast samples from leukocyte-rich RA and OA synovia. The gene averages for 
HLA-DRAhi sublining fibroblasts (SC-F2) and CD34+ sublining fibroblasts (SC-F1) were 
higher in leukocyte-rich RA compared to OA (t-test p=2×10−6 and p=2×10−3, respectively), 
while the gene averages for CD55+ lining fibroblasts (SC-F4) were higher in OA than 
leukocyte-rich RA (t-test p=5×10−7) (Fig. 4b).
Consistent with the role of synovial fibroblasts in matrix remodeling, the sublining fibroblast 
subsets (SC-F1–3) expressed genes encoding extracellular matrix constituents (Fig. 4c). 
HLA-DRAhi sublining fibroblasts (SC-F2) expressed genes related to MHC class II 
presentation and the interferon gamma-mediated signaling pathway (IFI30) (Fig. 4a,c), 
suggesting upregulation of MHC class II in response to interferon-gamma signaling in these 
cells. We identified a novel sublining fibroblast subtype (SC-F3) that is characterized by 
high expression of DKK3, CADM1 and COL8A2 (Fig. 4a).
To independently confirm the presence of four fibroblast subpopulations discovered by 
scRNA-seq, we analyzed CD45−PDPN+ cells in mass cytometry data, and found eight 
putative cell clusters with differential protein levels of THY1, HLA-DR, CD34, and 
Cadherin-11 without obvious batch effects (Fig. 4d–g, Supplementary Fig. 3b). CCA 
revealed that greater abundance of THY1+CD34−HLA-DRhi fibroblasts measured by mass 
cytometry is associated with higher expression of IL6, CXCL12, and HLA-DRA in bulk 
RNA-seq of the same samples, suggesting these cells are in an active cytokine-producing 
state (Fig. 4h). CCA allowed us to place mass cytometry clusters in the same space as bulk 
RNA-seq genes, so we could query the positions of scRNA-seq genes within this space to 
find the correspondence between scRNA-seq clusters and mass cytometry clusters (Fig. 4i, 
Methods). We found HLA-DRAhi sublining fibroblasts (SC-F2) correspond to 
THY1+CD34−HLA-DRhi fibroblasts (z-score=2.8), and CD34+ sublining fibroblasts (SC-
F1) correspond to THY1+CD34+HLA-DRlo fibroblasts (z-score=2.7) (Table 1). Consistent 
with differential expression analysis of bulk RNA-seq, we found that THY1+CD34−HLA-
DRhi cells in the mass cytometry data were overabundant in leukocyte-rich RA relative to 
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leukocyte-poor RA and OA controls (36% versus 2% of fibroblasts, MASC OR = 33.8 (95% 
CI: 11.7–113.1), one-sided MASC p=1.9×10−5) (Table 1).
To validate that the protein surface markers from mass cytometry were capturing the same 
transcriptional populations from scRNA-seq, we isolated fibroblasts from 10 synovial tissue 
samples based on surface protein levels of THY1 and HLA-DR and applied bulk RNA-seq 
(Supplementary Fig. 6a). We trained a linear discriminant analysis (LDA) classifier on 
fibroblast scRNA-seq data and used it to determine the most similar scRNA-seq cluster for 
each bulk RNA-seq sample. The sorted THY1+HLA-DR+ fibroblast population was similar 
to THY1+HLA-DRAhi (SC-F2) and the THY1− HLA-DR− population was similar to 
THY1− (SC-F4) (Supplementary Fig. 7a–d). Genes upregulated in the sorted THY1+HLA-
DR+ fibroblasts included the interleukin IL6 and the chemokine CXCL12, consistent with 
the scRNA-seq data.
Activation states define heterogeneity among synovial monocytes
We identified four transcriptionally distinct monocyte subsets in the scRNA-seq data: IL1B+ 
pro-inflammatory monocytes (SC-M1), NUPR1+ monocytes (SC-M2), C1QA+ monocytes 
(SC-M3) and IFN-activated SPP1+ monocytes (SC-M4) (Fig. 5a). In bulk RNA-seq 
monocyte samples from leukocyte-rich RA and OA donors, we found that genes associated 
with IL1B+ monocytes (SC-M1), including NR4A2, HBEGF, PLAUR and the IFN-activated 
gene IFITM3 were significantly upregulated in leukocyte-rich RA samples (t-test 
p<1×10−4). In contrast, marker genes associated with NUPR1+ monocytes (SC-M2) were 
downregulated in leukocyte-rich RA relative to OA (Fig. 5a). Next, we took the average of 
the top marker genes (AUC>0.7) for each monocyte scRNA-seq subset and tested for 
differential expression of these averages in the bulk RA versus OA RNA-seq data. This 
analysis suggests that leukocyte-rich RA synovia have a greater abundance of IL1B+ 
monocytes (t-test p=6×10−5) and IFN-activated monocytes (t-test p=6×10−3), but lower 
abundance of NUPR1+ monocytes (t-test p=2×10−5) (Fig. 5b). These data suggest that 
cytokine activation drives expansion of unique monocyte populations in active RA synovia.
With GSEA, we tested MSigDB immunologic gene sets and found IL1B+ monocytes (SC-
M1) have relatively high expression levels of genes defining the LPS response in monocytes 
and macrophages (Fig. 5b). This suggests IL1B+ monocytes (SC-M1) are similar to TLR-
activated IL-1-producing pro-inflammatory monocytes. Among Gene Ontology gene sets, 
we found SPP1+ monocytes (SC-M4) express genes induced by type I and II IFN 
(Supplementary Fig. 8a), including IFITM3 and IFI6 (Fig. 5a). The transcriptional profiles 
of monocytes in SC-M2 and SC-M3 do not align with known activation states, possibly 
indicating that these clusters represent cell phenotypes tailored to the unique homeostatic 
needs of the synovium. Immunofluorescence staining confirmed the presence of CD14 and 
IL-1β positive cells in 6 tissue samples, consistent with an enrichment of the IL1B+ pro-
inflammatory monocytes (SC-M1) phenotype in RA synovium (Fig. 5d, Supplementary Fig. 
9a,b).
In the mass cytometry data, we identified five CD14+ monocyte clusters (Fig. 5e–h, 
Supplementary Fig. 3c). Using CCA to integrate mass cytometry and bulk RNA-seq data, we 
found that samples with a greater abundance of CD11c+CCR2+ and CD11c+CD38+ using 
Zhang et al. Page 6
Nat Immunol. Author manuscript; available in PMC 2019 November 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
mass cytometry also had a higher expression of IFITM3, PLAUR, CD38, and HLA genes 
(Fig. 5i). This was consistent with a correspondence between the CD11c+CD38+ mass 
cytometry cluster and the activated monocyte scRNA-seq cluster IL1B+ (SC-M1) and SPP1+ 
(SC-M4) (z-score=2.3 and 2.3, respectively) (Fig. 5j, Table 1). Supporting this finding, we 
confirmed that CD11c+CD38+ monocytes are significantly expanded in leukocyte-rich RA 
(OR = 7.8 (95% CI: 3.6–17.2), one-sided MASC p=6.7×10−5) (Table 1). Conversely, 
NUPR1+ monocytes (SC-M2) correspond to CD11c− monocytes in mass cytometry and are 
inversely correlated with inflammatory monocyte populations (z-score=2.7) (Fig. 5j, Table 
1).
To confirm that putative populations from mass cytometry correspond to those identified by 
scRNA-seq clusters, we sorted CD14+ monocytes from 4 synovial tissue samples using 
CD11c and CD38 protein markers and assayed them with RNA-seq (Supplementary Fig. 
6c). Importantly, we found that CD14+ synovial cells had high expression of both CD11c 
and CD38 particularly in the RA samples. The CD14+CD11c+++CD38+++ and 
CD14+CD11c+CD38− sorted cells were consistent with IL1B+ pro-inflammatory (SC-M1) 
and NUPR1+ (SC-M2) cells, respectively (Supplementary Fig. 7e–h). These data, alongside 
the mass cytometry data, support the findings of greater abundance of IL1B+ pro-
inflammatory (SC-M1) monocytes and lower abundance of NUPR1+ (SC-M2) monocytes in 
leukocyte-rich RA samples.
Heterogeneity in synovial CD4 and CD8 T cells defined by effector functions
We found three CD4+ and three CD8+ T cell subsets in the scRNA-seq data (Fig. 6a). 
CCR7+ T cells (SC-T1) expressed genes in the MSigDB immunologic gene set for central 
memory T cells (Fig. 6a, c). The two other CD4+ populations, FOXP3+ Treg cells and 
PDCD1+ Tph and Tfh cells, were marked by high expression of FOXP3 (SC-T2) and 
CXCL13 (SC-T3) by examining differentially expressed genes between these two clusters18 
(Supplementary Fig. 8c). CXCL13, a chemokine expressed by Tph cells, was upregulated in 
bulk-sorted T cells (CD45+CD14−CD3+) from leukocyte-rich RA compared to OA (t-test 
p=1.2×10−4) (Fig. 6a). We found that the average of marker genes for Tph and Tfh cells 
(SC-T3) (AUC>0.7) was higher in leukocyte-rich RA than OA samples (t-test p=0.01) (Fig. 
6b), suggesting greater abundance of Tph and activated T cells in RA than OA. We 
identified three CD8 T cell subsets characterized by distinct expression patterns of effector 
molecules GZMK, GZMB, GZMA and GNLY (Fig. 6a). We defined these populations as 
GZMK+ (SC-T4), GNLY+GZMB+ cytotoxic T lymphocytes (CTLs) (SC-T5), and GZMK
+GZMB+ T cells (SC-T6). GZMK+GZMB+ T cells (SC-T6) also expressed HLA-DPA1 and 
HLA-DRB1, and other genes suggestive of an effector phenotype (Fig. 6a,c).
To confirm these findings, we applied intracellular staining to tissues from RA samples and 
RNA-seq to sorted CD8 T cells. Intracellular staining of GZMK and GZMB proteins in 
disaggregated tissue samples from patients with RA revealed that the majority of CD8 T 
cells in synovial tissue express GZMK (Supplementary Fig. 10a). Furthermore, we found 
that most HLA-DR+ CD8 T cells express both GZMB and GZMK by intracellular protein 
staining (Supplementary Fig. 10b). In a comparison of 7 synovial tissue samples, CD8 T 
cells had higher proportion of IFNγ+ cells than CD4 T cells from the same sample 
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(Supplementary Fig. 10c,d). We also applied immunofluorescence to 6 synovial tissue 
samples and found that IFNγ+CD3+CD8+ T cells were more frequent in RA than OA (Fig. 
6d, Supplementary Fig. 9c,d). Overall, these results closely mirror the findings from the 
scRNA-seq clusters.
Using mass cytometry, we identified nine putative T cell clusters among the synovial T cells 
(CD45+CD14−CD3+) (Fig. 6e–h, Supplementary Fig. 3d). By integrating bulk RNA-seq 
with mass cytometry cluster abundances, we found that higher gene expression of CXCL13 
and inhibitory receptors TIGIT and CTLA4 was associated with greater abundance of the 
CD4+PD-1+ICOS+ mass cytometry cluster. Greater abundance of CD8+ PD-1−HLA-DR+ 
cells was associated with greater expression of IFNG (Fig. 6i). We found correspondence 
between Tph and Tfh cells (SC-T3) and CD4+PD-1+ICOS+ T cells (z-score = 3.4). CD8+ 
subsets including GZMK+GZMB+ (SC-T6), CTLs (SC-T5), and GZMK+ (SC-T4) tracked 
with CD8+PD-1−HLA-DR+ T cells by mass cytometry (Fig. 6j, Table 1). In addition, 
CD4+PD-1+ICOS+ cells were significantly overabundant in leukocyte-rich RA (MASC OR 
= 3 (95% CI: 1.7–5.2), one-sided MASC p=2.7×10−4) (Table 1).
Autoimmune-associated B cells expanded in RA synovium by single-cell RNA-seq
We identified four synovial B cell clusters with scRNA-seq: naive B cells (SC-B1), memory 
B cells (SC-B2), ITGAX+ ABC cells (SC-B3), and plasmablasts (SC-B4) (Fig. 7a). GSEA 
with Gene Ontology pathways suggested that SC-B1, SC-B2, and SC-B3 clusters represent 
activated B cells (Supplementary Fig. 8b). GSEA with MSigDB immunological gene sets 
revealed that SC-B1 cells express naive B cell genes, while SC-B2 and SC-B3 cells express 
IgM and IgG memory B cell genes (Fig. 7b). SC-B3 cells express high levels of ITGAX and 
TBX21 (T-bet), which are markers of autoimmunity-associated B cells (Fig. 3f and Fig. 
7a)28,29, as well as markers of recently activated B cells including ACTB30. High expression 
of AICDA is consistent with the recently reported transcriptomic analysis of CD11c+ B cells 
from SLE peripheral blood31. Interferon stimulated genes (GBP1 and ISG15) are also 
expressed in ABCs (SC-B3) and upregulated in leukocyte-rich RA (Fig. 7a). While ABCs 
(SC-B3) constitute a relatively small proportion of all B cells, they are almost exclusively 
derived from two patients with leukocyte-rich RA (Fig. 3b). To confirm the presence of 
ABCs in human tissues, we applied immunofluorescence staining to 6 synovial tissue 
samples. RA synovium had increased numbers of CD20+T-bet+ CD11c+ B cells compared to 
OA synovium. Specifically, we observed ABC cells in tissue sections from the same 
inflamed tissue samples that had a high proportion of ABCs by scRNA-seq analysis (Fig. 7c, 
Supplementary Fig. 9e, f).
We identified 10 putative B cell clusters in the mass cytometry data 
(CD45+CD3−CD14−CD19+) (Fig. 7d–g, Supplementary Fig. 3e). CCA analysis showed that 
samples with higher gene expression of CD38, MZB1, and plasma cell differentiation factor 
XBP1 had greater abundance of CD38++CD20−IgM−IgD− plasmablasts (Fig. 7h). 
Plasmablasts (SC-B4) corresponded with CD38++CD20−IgM−IgD− B cells (z-score=2.7) 
(Fig. 7i, Table 1). ABCs (SC-B3) corresponded with the IgM− IgD− HLA-DR++ CD20+ 
CD11c+ mass cytometry cluster (z-score=1.6), which is significantly overabundant in 
leukocyte-rich RA (OR = 5.7 (95% CI: 1.8–22.3), one-sided MASC p=2.7×10−3) (Fig. 7i, 
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Table 1). Mass cytometry analysis further identified three putative subsets within CD11c+ 
cells: IgM−IgD−HLA-DR++CD20+CD11c+, CD38+HLA-DR++CD20−CD11c+, and IgM
+IgD+CD11c+, which is suggestive of additional heterogeneity within ABCs.
To demonstrate that CD19+CD11c+ cells by surface protein markers correspond to SC-B3 
(ABCs), we flow-sorted CD19+CD11c+ cells from an independent cohort of 6 RA synovial 
samples and applied RNA-seq (Supplementary Fig. 6b). We show that these RNA-seq 
profiles are most consistent with ABC cells (Supplementary Fig. 7i–k). In these sorted 
samples, we found more putative marker genes (e.g. ZEB2 and CIITA) and interferon-
induced genes (IFITM3 and IFI27) for the ABC population (Supplementary Fig. 7l).
Inflammatory pathways and effector modules revealed by global single cell profiling
We used bulk and single cell transcriptomes of sorted synovial cells to examine pathologic 
molecular signal pathways. First, principal component analysis (PCA) on post-QC OA and 
RA bulk RNA-seq samples (Supplementary Fig. 11a,b) showed that cell type accounted for 
most of the data variance. Each cell type expressed specific marker genes, PDGFRA for 
fibroblasts, C1QA for monocytes, CD3D for T cells, and CD19 for B cells (Supplementary 
Fig. 11c). Within each cell type, PCA showed that leukocyte-rich RA samples separated 
from OA and leukocyte-poor RA samples (Supplementary Fig. 11d–g). Differential gene 
expression analysis between leukocyte-rich RA and OA (FC>2 and FDR<0.01) revealed 
genes upregulated in leukocyte-rich RA tissues: 173 in fibroblasts, 159 in monocytes, 10 in 
T cells, and 5 in B cells. To define the pathways relevant to leukocyte-rich RA, we used 
GSEA weighted by gene effect sizes on Gene Ontology pathways and identified type I 
interferon response and inflammatory response (monocytes and fibroblasts) (Supplementary 
Fig. 11h–i), Fc receptor signaling (monocytes), NF-kappa B signaling (fibroblasts), and 
interferon gamma (T cells) (Fig. 8a). Leukocyte-rich RA samples had significantly higher 
expression of some genes in fibroblasts and monocytes: inflammatory response genes 
(PTGS2, PTGER3, and ICAM1), interferon response genes (IFIT2, RSAD2, STAT1, and 
XAF1), and chemokine or cytokine genes (CCL2 and CXCL9) (Fig. 8b), consistent with a 
coordinated chemotactic response to interferon activation. T cells had upregulation of 
interferon regulatory factors (IRFs), including IRF7 and IRF9, and monocytes had 
upregulation of IRF7, IRF8 and IRF9. Taken together, pathway analysis suggests crosstalk 
between immune and stromal cells in leukocyte-rich RA synovia. Inflammatory response 
genes upregulated in leukocyte-rich RA had comparable expression levels between 
leukocyte-poor RA and OA synovial cells (Fig. 8b)
Next, we asked whether inflammatory cytokines upregulated in leukocyte-rich RA are 
driven by global upregulation within a single synovial cell type, or specific upregulation 
within a discrete cell subset defined by scRNA-seq. Whereas TNF was produced at a high 
level by multiple monocyte, B cell and T cell populations; IL6 expression was restricted to 
HLA-DRAhi sublining fibroblasts (SC-F2) and a subset of B cells (SC-B1) (Fig. 8c); CD8 T 
cells, rather than CD4 T cells, were the dominant source of IFNG transcription in leukocyte-
rich synovia.
We also observed cell subset-specific responses to inflammatory pathways. Toll-like receptor 
signaling pathway was enriched in B cells and monocytes in leukocyte-rich RA tissues (Fig. 
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8a). At the single cell level, we observed that TLR10 was only expressed by activated B 
cells, indicating that TLR10 has a functional role within the B cell lineage. In contrast, 
TLR8 was elevated in all RA monocyte subsets. The hematopoietic cell-specific 
transcription factor IRF8 was expressed in a significant fraction of monocytes and B cells 
that cooperatively regulate differentiation of monocytes and activated B cells in RA 
synovium. SLAMF7 is highly expressed by pro-inflammatory monocytes (SC-M1), IFN-
activated monocytes (SC-M4), CD8 T cells, and plasmablasts (SC-B4).
Furthermore, mass cytometry analysis across all identified cell clusters revealed that 
leukocyte-rich RA patients show high cell abundances of HLA-DRhi fibroblast populations, 
Tph cells, CD11c+CD14+ monocytes, and CD11c+ B cell populations (Supplementary Fig. 
3f).
DISCUSSION
Using multi-model, high-dimensional synovial tissue data we defined stromal and immune 
cell populations overabundant in RA and described their transcriptional contributions to 
essential inflammatory pathways. Recognizing the considerable variation in disease duration 
and activity, treatment types, and joint histology scores32, we elected to use a molecular 
parameter, based on percent leukocytes of the total cellularity, to classify our samples at the 
local tissue level. We note that differences in leukocyte enrichment of joint replacement 
samples and biopsy samples were best explained by leukocyte infiltration and not by the 
histological scores (Supplementary Fig. 1, Supplementary Fig. 11d–g).
This study and a previous study33 have highlighted sublining fibroblasts as a potential 
therapeutic target in RA. Sublining fibroblasts are a major source of pro-inflammatory 
cytokines such as IL6 (Fig. 4), and a specific subset of sublining fibroblasts expressing 
MHC II (SC-F2, THY1+CD34-HLA-DRhi) was >15 fold expanded in RA tissues. Further 
studies are needed to define molecular mechanisms that regulate sublining fibroblast 
expansion in RA. T cells, B cells, and monocyte proportions track with expression of 
individual fibroblast genes (Supplementary Fig. 11j). We found DNASE1L3, a gene whose 
loss of function is associated with RA34 and systemic lupus erythematosus35 to be highly 
expressed in CD55+ lining fibroblasts (SC-F4) (Fig. 4a). We identified a novel fibroblast 
subset (SC-F3) with high expression of DKK3+ (Fig. 4), encoding Dickkopf3, a protein 
upregulated in OA that prevents cartilage degradation in vitro36.
Transcriptional heterogeneity in the synovial monocytes indicated that distinct RA-enriched 
subsets are driven by inflammatory cytokines and interferons (Fig. 5). This suggests 
monocytes may be differentially polarized by unique cytokine combinations in local 
microenvironments. These newly identified inflammatory phenotypes align with RA 
therapeutic targets, including anti-TNF therapies and interferon pathway JAK kinase 
inhibitors37. The NUPR1+ (SC-M2) monocytes were inversely correlated with tissue 
inflammation, and expressed high levels of monocyte tissue remodeling factors such as 
MERTK (Fig. 5)38. Alternatively, NUPR1+ markers such as osteoactivin (GPNMB) and 
cathepsin K (CTSK) may indicate a subset of osteoclast progenitors that control bone 
remodeling (Fig. 5)37,39. Furthermore, spatial studies—particularly focused on lining versus 
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sublining, perivascular and lymphocyte aggregate-associated monocytes—will help 
understand the functional roles of these subsets.
Single cell classification of T cell subsets in RA synovium demonstrated CD4+ T cell 
heterogeneity that is consistent with distinction between the homing capacity and effector 
functions of these subsets. Consistent with previous studies, we observed expansion of 
PDCD1+CD4+ Tph cells (SC-T3) within leukocyte-rich RA. We also found CD8 T cell 
subsets (SC-T4–6) characterized by a distinct granzyme expression pattern (Fig. 6a). A 
larger study may be better powered to differentiate the relative expansion of individual 
subpopulations.
A critical unmet need in RA is identifying therapeutic targets for patients failing to respond 
to disease-modifying antirheumatic drugs (DMARDs)41. We observed upregulation of 
chemokines (CXCL8, CXCL9, and CXCL13), cytokines (IFNG and IL1542,43), and surface 
receptors (PDGFRB and SLAMF7) in distinct immune and stromal cell populations, 
suggesting potential novel targets. This study was enabled by advances in the statistical 
integration of single-cell data and our recent work optimizing robust methodologies for 
disaggregation of synovial tissue22.
We developed advanced strategies to integrate multiple molecular datasets by modulating 
technical artifact from single cell technologies44, while emphasizing biological signals. CCA 
has been successfully employed in other contexts to integrate high-dimensional biological 
data45,46. Our CCA-based strategy analyzed scRNA-seq data using canonical variates that 
capture variance that are present in both single-cell and bulk RNA-seq data. The shared 
variances likely represent biological trends, and not technical factors that would likely be 
uncorrelated in these two independent datasets. We further confirmed that the identified 
scRNA-seq clusters are well correlated with the bulk RNA-seq data and also the mass 
cytometry data (Supplementary Fig. 12, 13).
The two single cell modalities used in this study, mass cytometry and scRNA-seq, 
complement each other. Single-cell RNA-seq captures expression of thousands of genes, but 
at the cost of sparse data47. Mass cytometry captures hundreds of thousands of individual 
cells, but measures a limited number (~40)48 of pre-selected markers. However, since 
markers are backed with decades of experimental experience they can be effective at 
defining cellular heterogeneity49. To make the analysis consistent, we gated mass cytometry 
cells on the same markers upon which the scRNA-seq was gated. Combining mass 
cytometry with the extended dimensionality of scRNA-seq enables quantification of well-
established cell populations and discovery of novel cell states, such as the CD8 T cell states 
noted here. As an ongoing AMP phase 2 study, we are examining larger numbers of ungated 
cell populations from ~100 synovial tissue patients with RA by capturing mRNA and protein 
expression simultaneously50 with detailed clinical data and ultrasound score evaluation of 
synovitis. We anticipate that this larger study will enable us to not only discover additional 
subpopulations, but to better define their link to clinical sub-phenotypes.
It is essential to interrogate the tissue infiltration of diseases other than RA, including SLE, 
type I diabetes, psoriasis, multiple sclerosis and other organ targeting conditions. 
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Application of multiple single-cell technologies together can help define key novel 
populations, thereby providing new insights about etiology and potential therapies.
Methods
Study design and patient recruitment
The study was performed in accordance with protocols approved by the institutional review 
board. A multicenter, cross-sectional study of individuals undergoing elective surgical 
procedures and a prospective observational study of synovial biopsy specimens from 
patients with RA ≥ age 18, with at least one inflamed joint, recruited from 10 contributing 
sites in the network. Synovial tissues were obtained from joint replacement procedures or 
ultrasound-guided biopsies, followed by cryopreservation in cryopreservation media 
Cryostor CS10 (Sigma-Aldrich) and transit to a central technology site.
Histological assessment of synovial tissue and quality control
Synovial tissue quality and grading of synovitis were evaluated in formalin-fixed, paraffin-
embedded sections by histologic analysis (H and E staining). Specimens were identified as 
synovium by the presence of a lining layer or by characteristic histologic features of 
synovium, including the presence of loose fibrovascular or fatty tissue lacking a lining layer. 
Samples consisting of dense fibrous tissue, joint capsule or other tissues were determined 
not to be synovium. For each histological and molecular analysis, we generated pooled data 
from 6–8 separate fragments from different sites in the same joint. Thus, this should be 
representative of the whole tissue and mitigate much of the biopsy site-to-site variability. 
Krenn lining scores (0–3) and inflammation scores (0–3) for each tissue sample were 
determined independently by three pathologists25.
Tissue disaggregation for mass cytometry and RNA-sequencing
For pipeline analysis, synovial tissue samples stored in cryovials were disaggregated into 
single cell suspension as describe. Briefly, synovial tissue fragments were separated 
mechanically and enzymatically in digestion buffer (Liberase TL (Sigma-Aldrich) 100 
ug/mL and DNase I (New England Biolabs) 100 ug/ml in RPMI) in a 37°C water bath for 30 
minutes. Single cell suspensions from disaggregated synovial tissues were assessed for cell 
quantity and cell viability by trypan Blue. For samples with more than 200,000 viable 
synovial cells, 50% of all synovial cells were allocated for analysis by mass cytometry and 
the remaining cells were allocated for RNA-seq. For samples with less than 200,000 viable 
synovial cells, all synovial cells were utilized for RNA-seq analysis.
Synovial cell sorting strategy for RNA sequencing
Synovial T cells, B cells, monocytes, and fibroblasts were isolated from disaggregated 
synovial tissue, as described22. Briefly, disaggregated synovial cells were stained with 
antibodies against CD45 (HI30), CD90 (5E10), podoplanin (NZ1.3), CD3 (UCHT1), CD19 
(HIB19), CD14 (M5E2), CD34 (4H11), CD4 (RPA-T4), CD8 (SK1), CD31 (WM59), CD27 
(M-T271), CD235a (KC16), using human TruStain FcX in 1% BSA in Hepes-Buffered 
Saline (HBS,20 mM HEPES, 137 mM NaCl, 3mM Kcl, 1mM CaCl2) for 30 minutes. 1000 
viable (PI-) T cells (CD45+, CD3+, CD14−), monocytes (CD45+, CD3−, CD14+), B cells 
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(CD45+, CD3−, CD14−, CD19+), and synovial fibroblasts (CD45−, CD31−, PDPN+) were 
collected by fluorescence-activated cell sorting (BD FACSAria Fusion) directly in buffer 
RLT (Qiagen) for bulk RNA-seq. For single cell RNA-seq, live cells of each population were 
re-sorted into 384-well plates single cells with a maximum of 144 cells for each cell type, 
per patient sample.
Flow sorting strategy for bulk RNA-seq experimental validation
For bulk RNA-seq validation experiments, RA and OA synovial tissue were disaggregated 
and synovial cells were stained with cell-type specific antibody panels. For each cell subset, 
up to 1000 cells were collected directly into buffer TCL (Qiagen). Antibody panels used to 
define cell subsets are fibroblasts: CD90 (5E10), podoplanin (NZ1.3), HLA-DR (G46–6); B 
cell subsets: HLA-DR (G46–6), CD11c (3.9), CD19 (SJ25C1), CD27 (M-T271), IgD (IA6–
2), CD3 (UCHT1), CD14 (M5E2), CD38 (HIT2); Monocyte subsets: CD14-BV421 (M5E2), 
CD38-APC (HB-7), and CD11c-PECy7 (B-ly6). Immediately prior to sorting, DAPI or 
LIVE/DEAD viability dye was added to cell suspensions and cells were passed through a 
100μm filter. Synovial cell subsets were sorted based on flow cytometry gating schema 
shown in Supplementary Fig. 6. In all, we sorted THY1− DR− populations from 4 OA 
samples, THY1+DR− population from 4 OA and 6 RA samples, and THY1+ DR+ population 
from 6 RA samples. For monocytes, we sorted CD14+CD11c+++CD38+++ population from 2 
RA samples and CD14+CD11c+ CD38− population from 2 OA samples. For B cells, we 
sorted CD11c−IgD−CD27+ population from 6 RA samples, CD11c−IgD+CD27− population 
from 3 RA samples, CD19+CD11c+ population from 3 RA samples, and plasma cells from 3 
RA samples.
To validate the identified single-cell populations using bulk RNA-seq, we fit an LDA (Linear 
Discriminant Analysis) classifier on the scRNA-seq cell clusters and then classified each 
flow sorted bulk RNA-seq sample. For each cell type, 1) we trained an LDA model on the 
scRNA-seq clusters with the top 500 marker genes for each cluster; 2) Next, we applied this 
LDA model to classify each sample of bulk sorted cells and estimated the maximum 
posterior probability for each sample. In summary, we tested if we could sort new cells from 
new, independent samples and see the same gene expression profiles in the new bulk 
samples as the original scRNA-seq samples.
Multicolor immunofluorescent staining of paraffin synovial tissue
Briefly, 5 mm thick formalin fixed paraffin sections were incubated in a 60°C oven to melt 
paraffin. Slides were quickly transferred to xylenes to completely dissolve the paraffin and 
after 5 minutes transferred to absolute ethanol. Slides were left in absolute ethanol for 5 
minutes and then transferred to 95% ethanol. At the end of the 5 minutes immersion in 95% 
ethanol, slides were rinsed several times with distilled water and transfer to a plastic coplin 
jar filled with 1× DAKO retrieval solution (S1699, Dakocytomation). Antigens were 
unmasked by immersing of plastic coplin jar in boiling water for 30 minutes. Slides were let 
cool down for 10 minutes at room temperature and washed several times with distilled water. 
Non-specific binding was blocked with 5% normal donkey serum (017-000-121, Jackson 
ImmunoResearch Laboratories,) dissolved in PBS containing 0.1% Tween 20 and 0.1% 
Triton X-100. Without washing, blocking solution was removed from slides and 
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combinations of primary antibodies were added to PBS containing 0.1% Tween 20 and 0.1% 
Triton X-100. Primary antibodies to detect IFNg+ T cells include goat anti-CD3 epsilon 
(clone M-20, Santa Cruz Biotechnology), mouse anti-human CD8 (clone 144B, GeneTex), 
and rabbit anti-human IFNg (Biorbyt, orb214082). To visualize ABC, we incubated slides 
with goat anti-human CD20 (LifeSpan Biosciences, LS-B11144), rabbit anti-Tbet (H-210, 
Santa Cruz Biotechnology) and biotinylated mouse anti-human CD11c (clone 118/A5, 
Thermo Fisher Scientific). To identify IL1B+ monocytes, we used a mixture of goat anti 
human CD14 (119–13402, RayBiotech) biotinylated rabbit anti-human IL1b (OABF00305-
Biotin, Aviva Systems Biology) and mouse anti-human CD16 (clone DJ130c, LifeSpan 
Biosciences). Finally, slides were probed with rabbit monoclonal anti-human CD90 (2694–
1, Epitomics), rat anti-human HLADR (cloneYE2/36 HLK, LifeSpan Biosciences) and 
mouse anti-human CD45 (clone F10-89-4, abcam) to detect fibroblasts, Class II expressing 
cells and hematopoietic cells, respectively. Slides with primary antibodies were incubated in 
a humid chamber at room temperature, overnight. Next morning, primary antibodies for 
triple T cell stain and for detecting ABC’s were revealed with Alexa Fluor 568 donkey anti-
goat IgG (A-11057, Thermo Fisher Scientific), Alexa Fluor 488 donkey anti-rabbit 
(771-546-152, Jackson ImmunoResearch Laboratories) and Alexa fluor 647 donkey anti-
mouse (715-606-151, Jackson ImmunoResearch Laboratories). Primary antibodies in the 
stain for monocytes were revealed with Alexa Fluor 568 donkey anti-goat Ig G, Alexa fluor 
488 streptavidin (S11223, Thermo Fisher Scientific) and Alexa Fluor 647 donkey anti-
mouse Ig G. Primary antibodies in the stain for fibroblasts and hematopoietic cells were 
detected with Cy3 donkey anti-rabbit (711-166-152, Jackson ImmunoResearch 
Laboratories), Alexa Fluor 488 donkey anti-rat Ig G (A-21208, Thermo Fisher Scientific) 
and Alexa Fluor 647 donkey anti-mouse Ig G. After 2 hours of incubation, slides were 
washed and mounted with Vectashield mounting media with DAPI (H-1200, Vector 
Laboratories). Pictures were taken with an Axioplan Zeiss microscope and recorded with a 
Hamamatsu camera. Double immunofluorescence pictures were obtained by merging 
individual channels in NIH Image J software.
Estimation of number of cells by counting nuclei
To estimate number of cells, we counted number of nuclei in 5 random 200× fields that show 
synovial lining with Image J NIH software. Briefly, original color TIFF files were first 
transformed into 8-bit grayscale images. We use similar settings to adjust threshold in 8-bit 
images (Lower threshold level: 0, Upper threshold level: 60). Next, we used process: binary: 
watershed to separate nuclei. In the analyze icon, we select analyze particles and we use 
equal settings to count particles in our images (Size (pixel2): 50-infinity, circularity 0.00–
1.00, Show: outlines) and we selected to display results. We visually confirmed that 
individual nuclei were outlined in the final image and calculate the average number of cells/
200× field in individual samples.
Tissue samples classification based on leukocyte infiltration
We classified RA tissue samples into leukocyte-poor RA and leukocyte-rich RA based on 
Mahalanobis distance from OA samples computed on leukocyte abundance measured by 
flow cytometry. We first took OA samples as a reference, and calculated a multivariate 
normal distribution of the percentages of live T cells, B cells, and monocytes. Here we used 
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the mahalanobis function in R: data x = a matrix of all 51 samples by flow gates of T cells, 
B cells, and monocytes; center = mean of T cells, B cells, and monocytes for all OA 
samples; covariance = covariance of T cells, B cells, and monocytes for all OA samples. We 
calculated the square root to get Mahalanobis distance for each sample,
mah = x − μ 'Σ−1 x − μ .
We then defined the maximum value of all OA samples (4.5) as a threshold to define 19 
leukocyte-rich RA (>4.5) and 17 leukocyte-poor RA (<4.5) samples in our cohort 
(Supplementary Fig. 1d).
Bulk RNA-seq gene expression quantification
We sorted cells into the major immune and stromal cell populations: T cells, B cells, 
monocytes and synovial fibroblasts. We then performed RNA sequencing. Full-length cDNA 
and sequencing libraries were performed using Illumina Smart-eq2 protocol51. Libraries 
were sequenced on MiSeq from Illumina to generate 35 base paired-end reads. Reads were 
mapped to Ensembl version 83 transcripts using kallisto 0.42.4 and summed expression of 
all transcripts for each gene to get transcripts per million (TPM) for each gene.
Bulk RNA-seq quality control
For quality control of bulk RNA-seq data, we began by defining common genes as the set of 
genes detected with at least 1 mapped fragment in 95% of the samples. Then, for each 
sample, we computed the percent of common genes detected in that sample. Low quality 
samples are those that have less than 99% of common genes detected, and these were 
discarded. We found that the low-quality samples also had low cell counts (Supplementary 
Fig. 11a). After discarding 25 low quality samples, we used 167 good quality samples, 
including 45 fibroblast samples, 46 monocyte samples, 47 T cell samples, and 29 B cell 
samples in all bulk RNA-seq analyses. Cell lineage markers, PDGFRA, C1QA, CD3D, and 
CD19, are expressed selectively by fibroblasts, monocytes, T cells, and B cells, respectively 
(Supplementary Fig. 11c).
Single-cell RNA-seq gene expression quantification
Single-cell RNA-seq was performed using the CEL-Seq2 method47 with the following 
modifications. Single cells were sorted into 384-well plates containing 0.6 μL 1% NP-40 
buffer in each well. Then, 0.6 μL dNTPs (10mM each; NEB) and 5 nl of barcoded reverse 
transcription primer (1 μg/μL) were added to each well along with 20 nL of ERCC spike-in 
(diluted 1:800,000). Reactions were incubated at 65°C for 5 min, and then moved 
immediately to ice. Reverse transcription reactions were carried out, as previously described 
(Hashimshony et al., 2016), and cDNA was purified using 0.8× volumes of Agencourt 
RNAClean XP beads (Beckman Coulter). In vitro transcription reactions (IVT) were 
performed, as described followed by EXO-SAP treatment. Amplified RNA (aRNA) was 
fragmented at 80°C for 3 min and purified using Agencourt RNAClean XP beads (Beckman 
Coulter). The purified aRNA was converted to cDNA using an anchored random primer and 
Illumina adaptor sequences were added by PCR. The final cDNA library was purified using 
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Agencourt RNAClean XP beads (Beckman Coulter). Paired-end sequencing was performed 
on the HiSeq 2500 in High Output Run Mode with a 5% PhiX spike-in using 15 bases for 
Read 1, 6 bases for the Illumina barcode and 36 bases for Read 2. We mapped Read2 to 
human reference genome hg19 using STAR 2.5.2b, and removed samples with outlier 
performance using Picard. We quantified gene levels by counting UMIs (Unique Molecular 
Identifiers) and transforming the counts to Log2(CPM+1) (Counts Per Million).
Single-cell RNA-seq quality control
For quality control of single-cell RNA-seq data, we filtered out molecules that are likely to 
be contamination between cells, and we used several metrics to exclude poor quality cells. 
We identified molecules that are likely to represent cell-to-cell cross-contamination as 
follows. Many single-cell RNA-seq library preparation protocols include pooling and 
amplification of cDNA molecules from a large number of cells. This can introduce cell-to-
cell contamination. We found that molecules represented by a small number of reads are 
more likely to be contaminant molecules derived from other cells. We developed a simple 
algorithm to set a threshold for the minimum number of reads per molecule, and we ran it 
separately for each quadrant of 96 wells in each 384-well plate. We used 2 marker genes 
expected to be exclusively expressed in each of the 4 cell types: PDGFRA and ISLR for 
fibroblasts, CD2 and CD3D for T cells, CD79A and RALGPS2 for B cells, and CD14 and 
C1QA for monocytes. We counted nonzero expression of these genes in the correct cell type 
as a true positive and nonzero expression in the incorrect cell type as a false positive. Then 
we tried each threshold for reads per molecule from 1–20 and chose the threshold that 
maximizes the ratio of true positive to false positive (Supplementary Fig. 14). This left us 
with 7,127 cells and 32,391 genes. Next, we discarded cells with fewer than 1,000 genes 
detected with at least one fragment. We also discarded cells that had more than 25% of 
molecules coming from mitochondrial genes. This left us with 5,265 cells. We discarded 
genes that had nonzero expression in fewer than 10 cells. We show all post-QC single cells 
based on the number of genes detected and percent of molecules from mitochondrial genes 
for each identified cluster (Supplementary Fig. 15).
Mass cytometry sample processing and quality control
We collected 6 leukocyte-rich, 9 leukocyte-poor RA, and 11 OA samples for mass cytometry 
analysis, and processed the samples, as described previously22. Briefly, we analyzed samples 
on a Helios instrument (Fluidigm) after antibody staining and fixation (Supplementary Table 
2). Mass cytometry data were normalized using EQ™ Four Element Calibration Beads 
(Fluidigm), as previously described52. Cells were first gated to live DNA+ cells prior to 
gating for specific cell populations using the following scheme: B cells 
(CD3−CD14−CD19+), fibroblasts (CD45−PDPN+), monocytes (CD3−CD14+), and T cells 
(CD3+CD14−). All biaxial gating was performed using FlowJo 10.0.7.
Integrative computational pipeline for scRNA-seq clustering
We developed a graph-based unbiased clustering pipeline based on canonical correlation 
analysis to take advantage of the shared variation between single-cell RNA-seq and bulk 
RNA-seq. We used this computational pipeline to analyze single cells from each cell type. 
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The overall flowchart is shown in Supplementary Fig. 2. We describe the details of each step 
as follows:
1. We first selected the highly variable genes such that the mean and standard 
deviation are in the top 80% of the density distributions from the single-cell 
RNA-seq matrix C (g genes by m cells, c1,…,m) and bulk RNA-seq matrix (g 
genes by n samples, s1,…,n), respectively. We focused on the highly variable 
genes detected in both scRNA-seq and bulk RNA-seq datasets.
2. Based on the shared highly variable genes, we integrated single-cell RNA-seq 
with bulk RNA-seq by finding a linear projection of bulk samples and single 
cells such that the correlation between the genes are maximized using the CCA 
method53. CCA finds two vectors a and b that maximize the linear correlations 
cor(CVs1,CVc1) where CVs1 = a1s1 + a2s2 +…+ ansn and 
CVc1 = b1c1 + b2c2 +…+ bmcm. Each bulk sample si gets a coefficient ai and each 
cell ci gets a coefficient bi. The linear combination of all samples s1,…,n arranges 
bulk genes along the canonical variate CVs1 and the linear combination of all 
cells c1,…,m arranges single-cell genes along CVc1 CCA defines the coefficients 
a1,…,n and b1,…,n that arrange the genes from the two datasets in such a way that 
the correlation between CVs1 and CVc1 is maximized. After CCA finds the first 
pair of canonical variates, the next pair is computed on the residuals, and so on.
3. We calculated the cell-to-cell similarity matrix using Euclidean distance on the 
top ten CCA canonical variates.
4. We built up a K-nearest neighbors (KNN) graph based on the cell-to-cell 
similarity matrix (Euclidean distance) based on local ordinal embedding (LOE), 
a graph embedding method. We then converted the KNN neighbor relation 
matrix into an adjacency matrix using the graph.adjacency function from igraph 
R package;
5. We clustered the cells using the Infomap algorithm for community detection by 
applying a cluster_infomap function from igraph R package to decompose the 
cell-to-cell adjacency matrix into major modules by minimizing a description of 
the information flow;
6. We then constructed a low dimensional embedding using tSNE based on the cell-
to-cell distance matrix using the following parameters: perplexity = 50 and theta 
= 0.5;
7. We identified and prioritized significantly differentially expressed genes for each 
distinct cluster based on percent of non-zero expressing cells, AUC score54, and 
fold-change;
8. For pathway analysis, we downloaded gene sets from Gene Ontology (GO) terms 
on April 201755,56. This included 9,797 GO terms and 15,693 genes. We also 
used the immunological signatures from 4872 hallmark gene sets from 
MSigDB57 to test enrichment of all the tested genes sorted by decreased AUC 
Zhang et al. Page 17
Nat Immunol. Author manuscript; available in PMC 2019 November 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
scores for each cluster by 105 permutation tests55. We used the liger R package 
(https://github.com/JEFworks/liger) to do gene set enrichment analysis (GSEA).
To identify the most reasonable and stable clusters, we ran this pipeline repeatedly while 
tuning the number of top canonical variates (4, 8, 12, 16, and 20) that were incorporated for 
the cell-to-cell similarity matrix, and the number of k (50, 100, 150, 200, 250, and 300) to 
build up the K-nearest neighbors’ graph. We chose the clusters that yielded the greatest 
number of differentially expressed genes. We used Silhouette analysis58,59 on the cell-to-cell 
Euclidean distance matrix to evaluate our clustering results (Supplementary Fig. 2b). For 
each cell, the silhouette width s(i) is defined as follows:
s i = b i − a imax a i ,   b i ,
where a(i) is the average dissimilarity between a cell and all the other cells in the same 
cluster and b(i) is the average distance between a cell and all cells in the nearest cluster to 
which the cell does not belong. The measure range is [−1, 1], where a value near 1 indicates 
a cell is far from neighboring clusters, a value near 0 indicates a cell is near a decision 
boundary, and a value near −1 indicates the cell is closer to a neighboring cluster than its 
own cluster.
Thus, for each pair of single-cell RNA-seq and bulk RNA-seq, we ran our pipeline on the 
shared samples that have both datasets for each cell type (Figure 1b). For integrating 
fibroblast data, we used 45 bulk RNA-seq samples, 1,844 single cells and 7,016 shared 
highly variable genes; for integrating monocyte data, we used 47 bulk RNA-seq samples, 
750 single cells and 7,016 shared highly variable genes; for integrating T cell data, we used 
47 bulk RNA-seq samples, 1,716 single cells and 7,003 shared highly variable genes; for 
integrating B cell data, we used 29 bulk RNA-seq samples, 1,142 single cells and 7,023 
shared highly variable genes.
Mass cytometry clustering
We created mass cytometry datasets for analysis by concatenating cells from all individuals 
for each cell type. For donors with more than 1,000 cells, we randomly selected 1,000 cells 
to ensure that samples were equally represented. In this way, we created downsampled 
datasets of 25,161 fibroblasts from 23 patients, 15,298 monocytes from 26 patients, 19,985 
T cells from 26 patients, and 8,179 B cells from 23 patients for analysis. We then applied the 
tSNE algorithm (Barnes-Hut implementation) to each dataset using the following 
parameters: perplexity = 30 and theta = 0.5. We used all markers except those used to gate 
each population in the SNE clustering. To identify high-dimensional populations, we used a 
modified version of DensVM23. DensVM performs kernel density estimation across the 
dimensionally reduced SNE map to build a training set, then assigns cells to clusters by their 
expression of all markers using an SVM classifier. We modified the DensVM code to 
increase the range of potential bandwidths searched during the density estimation step and to 
return the SVM model generated from the tSNE projection. We summarized the details of 
the clusters with proportion of cells from each disease cohort in Supplementary Table 3.
Zhang et al. Page 18
Nat Immunol. Author manuscript; available in PMC 2019 November 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Disease association test of cell populations
We tested whether abundances of individual populations were altered in RA case samples 
compared to OA controls using two ways. First, we assessed whether marker genes (AUC > 
0.7, 20 < n < 100) characteristic of each scRNA-seq cluster were differentially expressed in 
the same direction in scRNA-seq and bulk RNA-seq datasets. Second, we applied MASC19, 
a single cell association method for testing whether case-control status influences the 
membership of single cells in any of multiple cellular subsets while accounting for technical 
confounds and biological variation. We specified donor identity and batch as random-effect 
covariates.
Integration of bulk RNA-seq with mass cytometry
We used CCA to associate the abundances of mass cytometry clusters with gene expression 
in bulk RNA-seq. We started by selecting the samples that had both data types. The mass 
cytometry data matrix has samples and clusters, where the values represent proportions of 
cells from each sample in each cluster. The bulk RNA-seq data matrix has samples and 
genes, where the values represent proportions of gene abundance from each sample in each 
gene. CCA identifies canonical variates (a linear combination of bulk RNA-seq genes and a 
linear combination of mass cytometry cluster proportions) that maximize correlation of 
samples along each canonical variate. In other words, it tries to arrange samples from each 
dataset in a similar order along each canonical variate. We ran CCA separately for 
fibroblasts, monocytes, T cells, and B cells. For fibroblasts, we associated 2,299 genes with 
8 mass cytometry clusters on 22 samples. For monocytes, we associated 2,161 genes with 5 
mass cytometry clusters on 25 samples. For T cells, we associated 2,255 genes with 9 mass 
cytometry clusters on 26 samples. For B cells, we associated 22,95 genes with 10 mass 
cytometry clusters on 17 samples.
Finding correspondence between scRNA-seq clusters and mass cytometry clusters
1) For each cell type, we ran CCA with mass cytometry clusters with bulk RNA-seq. Each 
gene is correlated with each canonical variate (CV). Also, each mass cytometry cluster is 
correlated with each CV. By visualizing these correlations, we can see the positions of bulk 
RNA-seq genes and mass cytometry clusters in the same space (Figure 4h).
2) We then associated single-cell RNA-seq clusters with mass cytometry clusters by 
projecting cluster markers (AUC > 0.7) for each single-cell RNA-seq cluster in the CCA 
space acquired from step 1).
3) We took the average across the cluster marker genes for each single-cell RNA-seq cluster 
for each CV and obtained an “average CV” matrix.
4) Based on the “average CV” matrix, we computed Spearman correlation between the 
scRNA-seq average CV and the CV for mass cytometry clusters.
5) Next, we generated a null distribution for the Spearman correlations by shuffling the 
scRNA-seq gene names and then repeating steps 2–4 10,000 times.
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6) For the 10,000 replicates of CCA matrix, we repeated from step 2 to step 5. Then, we 
counted how many times the correlation of each pair was greater than the observed value 
from step 4).
permutation   p   =  
1   +   sum(corperm > cor)
1   +   1e4
.
7) Finally, we converted the to a permutation p to a z − score.
Differential expression analysis with bulk RNA-seq
We classified all the samples into OA, leukocyte-poor RA, and leukocyte-rich RA synovial 
tissues based on the quantitative analysis of T cells, B cells, and monocytes by flow 
cytometry. PCA on bulk RNA-seq samples showed separation of leukocyte-rich and 
leukocyte-poor RA on the first or second principal components. For differential analysis, we 
used the limma R package to identify significantly differentially expressed genes. We used 
the Benjamini-Hochberg method to estimate false discovery rate (FDR).
Identification of markers for distinct scRNA-seq clusters
Based on the single-cell RNA-seq clusters, we identified cluster marker genes by comparing 
the cells in one cluster with all other clusters from the same cell type, based on Log2(CPM
+1). We prioritized cluster marker genes using three criteria: 1) percent of non-zero 
expressing cells > 60%; 2) are under the receiver-operator curve (AUC)54 > 0.7; and 3) fold-
change (FC) > 2.
Intracellular flow cytometry of synovial tissue T cell stimulation
Disaggregated synovial tissue cells were incubated with Fixable Viability Dye (eBioscience) 
and Fc blocking antibodies (eBioscience) followed by staining for surface markers in 
Brilliant Stain Buffer (BD Bioscience). Cell were then fixed and permeabilized using an 
intracellular staining kit (eBioscience), followed by intracellular staining for granzymes or 
cytokines. Antibodies used in this study include anti-CD45 (clone HI30) from BD 
Biosciences; anti-CD3 (clone UCHT1), anti-CD8 (clone SK1), anti-CD14 (clone M5E2), 
anti-CD4 (clone RPA-T4), anti-HLA-DR (clone L243), anti-granzyme B (clone GB11), and 
anti-granzyme K (clone GM26E7) from Biolegend; and anti-IFNG (clone 4S.B3) and anti-
TNF (clone MAb11) from eBioscience. Data were collected on a BD Fortessa flow 
cytometer and analyzed using FlowJo 10.5 software. Disaggregated synovial tissue cells 
were incubated with a cell stimulation cocktail containing PMA and ionomycin 
(eBioscience) in RPMI with 10% fetal calf serum (Gemini). After 15 minutes, brefeldin A 
(eBioscience) was added. The cells were incubated at 37C 5% CO2 for an additional 2 
hours. The cells were then collected and stained for intracellular cytokines following the 
protocol above and the data was shown in Supplementary Fig. 10.
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Statistics
Results are shown as mean with 95% confidence intervals. The statistics tests used were t-
test and Kolmogorov-Smirnov test, unless otherwise stated, as described with one-sided or 
two-sided in the figure legends. Benjamini-Hochberg FDR < 0.01 and Fold-change > 2 were 
considered to be statistically significant when appropriate.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overview of synovial tissue workflow and pairwise analysis of high-dimensional data. a. We 
acquired synovial tissue, disaggregated the cells, sorted them into four gates representing 
fibroblasts (CD45−CD31−PDPN+), monocytes (CD45+CD14+), T cells (CD45+CD3+), and 
B cells (CD45+CD3−CD19+). We profiled these cells with mass cytometry, flow cytometry, 
sorted low-input bulk RNA-seq, and single-cell RNA-seq. Here, we use Servier Medical Art 
by Servier for the joint picture. b. Presence and absence of five different data types for each 
tissue sample. c. Schematic of each dataset and the shared dimensions used to analyze each 
of the three pairs of datasets with canonical correlation analysis (CCA). d. CCA finds a 
common mapping for two datasets. For bulk RNA-seq and single-cell RNA-seq, we first find 
a common set of g genes present in both datasets. Each bulk sample si gets a coefficient ai 
and each cell ci gets a coefficient bi. The linear combination of all samples s1…n arranges 
bulk genes along the canonical variate CVs1 and the linear combination of all cells c1…m 
arranges single-cell genes along CVc1. CCA finds the coefficients a1…n and b1…m that 
arrange the genes from the two datasets in such a way that the correlation between CVs1 and 
CVc1 is maximized. After CCA finds the first pair of canonical variates, the next pair is 
computed on the residuals, and so on.
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Figure 2. 
Distinct cellular composition in synovial tissue from OA, leukocyte-poor RA, and 
leukocyte-rich RA patients. a. Histological assessment of synovial tissue derived from OA 
(n = 15 independent tissue samples), leukocyte-poor RA (n = 17 independent tissue 
samples), and leukocyte-rich RA (n = 19 independent tissue samples). b. Cellular 
composition of major synovial cell types by flow cytometry. c. Synovial T cells, B cells, and 
monocytes by flow cytometry in samples from OA (n = 15), leukocyte-poor RA (n = 17), 
and leukocyte-rich RA (n = 19). Leukocyte-rich RA tissues were significantly higher 
infiltrated in synovial T cells (Student’s one-sided t-test P = 4×10−9, t-value = 8.92, df = 
22.27) compared to leukocyte-poor RA and OA. Leukocyte-rich RA tissues were 
significantly higher infiltrated in synovial B cells (Student’s one-sided t-test P = 1×10−3, t-
value = 3.50, df = 20.56) compared to leukocyte-poor RA and OA. Center value is mean. 
Statistical significance levels: ****P<1×10−4 and ***P<1×10−3. d. Quantitative histologic 
inflammatory scoring of both sublining cell layer and lining layer. Leukocyte-rich RA 
samples (n = 19) exhibited higher (Student’s one-sided t-test P = 1×10−3, t-value = 3.21, df 
= 30.66) Krenn inflammation scores than leukocyte-poor RA (n=15) and OA tissues (n = 10) 
samples. Center value is mean. e. Correlation between leukocyte infiltration assessed by 
cytometry with histologic inflammation score (n = 44 biologically independent samples). 
Student’s one-sided t-test P = 3×10−09, t-value = 7.15, df = 46.51. f. tSNE visualization of 
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synovial cell types in OA, leukocyte-poor RA, and leukocyte-rich RA by mass cytometry 
density plot.
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Figure 3. 
High-dimensional transcriptomic scRNA-seq clustering reveals distinct cell type 
subpopulations. a. 18 clusters across 5,265 cells from all cell types on a tSNE visualization. 
b. Cluster abundances across donors. c. Fibroblasts: three types of THY1+ sublining 
fibroblasts (SC-F1, SC-F2, and SC-F3) and CD55+ lining fibroblasts (SC-F4). d. 
Monocytes: two activated cell states of IL1B+ pro-inflammatory (SC-M1) and IFN-activated 
(SC-M4) monocytes. e. T cells: CD4+ subsets: SC-T1, SC-T2, SC-T3, and CD8+ subsets: 
SC-T4, SC-T5, and SC-T6. f. B cells: HLA+ (SC-B1, SC-B2, and SC-B3) and plasmablasts 
(SC-B4). The cluster colors in c-f are consistent with (a).
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Figure 4. 
Distinct synovial fibroblast subsets defined by cytokine activation and MHC II expression. a. 
scRNA-seq analysis identified three sublining subsets, CD34+ (SC-F1), HLAhi (SC-F2), and 
DKK3+ (SC-F3) and one lining subset (SC-F4). Differential analysis between leukocyte-rich 
RA (n = 16) and OA (n = 12) bulk RNA-seq fibroblast samples shows marker genes 
upregulated or downregulated in leukocyte-rich RA. Fold changes with 95% confidence 
interval (CI). b. By querying the leukocyte-rich RA (n = 16) and OA (n = 12) fibroblast bulk 
RNA-seq samples, scRNA-seq cluster HLA-DRAhi (SC-F2) and CD34+ (SC-F1) fibroblasts 
are significantly overabundant (two-sided Student’s t-test P=2×10−6, t-value=6.2, df = 23.91 
and P=2×10−3, t-value = 3.20, df = 25.41, respectively) in leukocyte-rich RA relative to OA. 
Lining fibroblasts (SC-F4) are overabundant (two-sided Student’s t-test P=5×10−7, t-value=
−5.31, df =21.97) in OA samples. Fold changes with 95% CI. c. Pathway enrichment 
analysis for each cluster. Two-sided Kolmogorov-Smirnov test with 105 permutations; 
Benjamini-Hochberg FDR is shown. d-e. Identified subpopulations from fibroblasts (n = 
25,161) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 8 OA by 
mass cytometry on the same gating with scRNA-seq. f-g. Normalized intensity of distinct 
protein markers shown in tSNE visualization and averaged for each cluster heatmap. h. CCA 
projections of mass cytometry clusters and bulk RNA-seq genes. First two canonical variates 
(CVs) separated genes upregulated in leukocyte-rich RA from genes upregulated in OA. 
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HLAhi genes are highly associated with THY1+CD34−HLA-DRhi by mass cytometry. i. 
Integration of mass cytometry clusters with scRNA-seq clusters based on the top markers 
(AUC > 0.7) for each scRNA-seq cluster using top 10 canonical variates in the low-
dimensional CCA space. We computed the spearman correlation between each pair of 
scRNA-seq cluster and mass cytometry cluster in the CCA space and performed permutation 
test 104 times. Z-score is calculated based on permutation p-value. We observed HLAhigh 
sublining fibroblasts by scRNA-seq are strongly correlated with THY1+CD34−HLA-DRhi 
fibroblasts by mass cytometry.
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Figure 5. 
Unique activation states define synovial monocytes heterogeneity. a. scRNA-seq analysis 
identified four subsets: IL1B+ pro-inflammatory monocytes (SC-M1), NUPR1+ monocytes 
(SC-M2) with a mixture of leukocyte-poor RA and OA cells, C1QA+ (SC-M3), and IFN-
activated monocytes (SC-M4). Differential analysis by bulk RNA-seq on leukocyte-rich RA 
samples (n = 17) and OA samples (n = 13) revealed upregulation/downregulation of cluster 
marker genes. Effect sizes with 95% CI are given. b. By querying the bulk RNA-seq, we 
found scRNA-seq cluster IL1B+ pro-inflammatory monocytes (two-sided Student’s t-test 
P=6×10−5, t-value=4.56, df =26.33) and IFN-activated monocytes (two-sided Student’s t-test 
P=6×10−3, t-value=3.28, df =23.68) are upregulated in leukocyte-rich RA (n = 17) compared 
to OA (n = 13), while SC-M2 is depleted (two-sided Student’s t-test P=2×10−5, t-value=
−5.62, df=26.81) in leukocyte-rich RA. Error bars indicate mean and 95% CI. c. Pathway 
enrichment analysis indicates the potential pathways for each subset. Two-sided 
Kolmogorov-Smirnov test with 105 times permutation was performed; Benjamini-Hochberg 
was used to control the FDR of multiple tests. The standard names for the immunological 
gene sets from up to bottom are: Genes down-regulated in neutrophils versus monocytes 
(GSE22886); Genes down-regulated in healthy myeloid cells versus SLE myeloid cells 
(GSE10325); Genes down-regulated in control microglia cells versus those 24 h after 
stimulation with IFNG (GSE1432); Genes down-regulated in unstimulated macrophage cells 
versus macrophage cells stimulated with LPS (GSE14769); Genes up-regulated monocytes 
treated with LPS versus monocytes treated with control IgG (GSE9988); Genes up-regulated 
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in monocytes versus myeloid dendritic cells (mDC) (GSE29618); Genes up-regulated in 
monocytes versus plasmacytoid dendritic cells (pDC) (GSE29618). d. Detection of pro-
inflammatory IL-1β in inflamed synovium by multicolor immunofluorescent staining with 
antibodies CD14 (red), IL-1β (green), and counterstained with DAPI (blue) identified 
CD14+IL-1β+ cells (white arrow). The experiment was repeated > 5 times with staining of 6 
independent leukocyte-rich RA samples with similar results. Image was acquired at 200 
magnification. Scale bar is 50 μm. e–f. Identified subpopulations from monocytes (n = 
15,298) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 11 OA by 
mass cytometry on the same gating with scRNA-seq. g-h. Normalized intensity of distinct 
protein markers by tSNE visualization and averaged for each cluster in heatmap. i. 
Integration of identified mass cytometry clusters with bulk RNA-seq reveals genes that are 
associated with CD11c+CD38+ and CD11c+CCR2+, like IFITM3, CD38, HBEGF, ATF3, 
and HLA+ genes. j. Integration of mass cytometry clusters and scRNA-seq clusters revealed 
that CD11c+CD38+ by mass cytometry are significantly associated with IL1B+ pro-
inflammatory (SC-M1) monocytes.
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Figure 6. 
Synovial T cells display heterogeneous CD4 and CD8 T cell subpopulations in RA 
synovium. a. scRNA-seq analysis identified three CD4+ subsets: CCR7+ (SC-T1), Treg cells 
(SC-T2), and Tph and Tfh (SC-T3); and three CD8+ subsets: GZMK+ (SC-T4), CTLs (SC-
T5), and GZMK+GZMB+ (SC-T6). Differential expression analysis on leukocyte-rich RA (n 
= 18) comparing with OA (n = 13) on sorted T cell bulk RNA-seq samples revealed that 
CXCL13 is most significantly enriched in leukocyte-rich RA compared to OA. Effect sizes 
with 95% CI are given. b. Disease association of scRNA-seq clusters by aggregating top 
markers (AUC>0.7) by comparing leukocyte-rich RA (n = 18) with OA (n = 13) using bulk 
RNA-seq. Tph and Tfh cells (SC-T4) are upregulated (two-sided Student’s t-test p=0.01, t-
value=2.73, df =29.00) in leukocyte-rich RA. Error bars indicate mean and 95% CI. c. 
Pathway analysis based on immunologic gene set enrichment indicates the potential 
enriched T cell states pathways. Two-sided Kolmogorov-Smirnov test with 105 times 
permutation was performed; Benjamini-Hochberg was used to control the FDR of multiple 
tests. The brief description of the standard names from up to bottom are: Genes up-regulated 
in CD4 high cells from thymus: Treg versus T conv (GSE42021); Genes up-regulated in 
comparison of effector CD8 T cells versus memory CD8 T cells (GOLDRATH); Genes 
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down-regulated in comparison of effector memory T cells versus central memory T cells 
from peripheral blood mononuclear cells (PBMC) (GSE11057); Genes up-regulated in 
comparison of effective memory CD4 T cells versus Th1 cells (GSE3982); Genes up-
regulated in comparison of T follicular helper (Tfh) cells versus Th17 cells (GSE11924). d. 
Detection of CD3+CD8+IFNγ+ (white arrow) in inflamed RA synovium by multicolor 
immunofluorescent staining with antibodies CD3 (green), CD8 (red), IFNγ (white), and 
counterstained with DAPI (blue). The experiment was repeated > 5 times with staining of 6 
independent leukocyte-rich RA samples with similar results. Image was acquired at 200 
magnification. Scale bar is 50 μm. e-f. Identified subpopulations from T cells (n = 19,985) 
and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 11 OA by mass 
cytometry. g-h. Distinct patterns of protein markers by tSNE and heatmap that define these 
clusters. i. Integration of identified mass cytometry clusters with bulk RNA-seq using CCA 
reveals bulk genes that are associated with CD4+PD-1+ICOS+ and CD8+PD-1−HLA-DR+ by 
mass cytometry. j. Integration of mass cytometry clusters with scRNA-seq clusters on the 
top markers (AUC>0.7) for each scRNA-seq cluster in the top 10 canonical variates. Z-score 
based on permutation test reveals that CD4+PD-1+ICOS+ and CD8+PD-1+HLA-DR+ by 
mass cytometry are highly associated with Tph and Tfh (SC-T3) by scRNA-seq; 
CD8+PD-1−HLA-DR+ T cells by mass cytometry are highly associated with CD8+ T cells 
(SC-T4, SC-T5, and SC-T6).
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Figure 7. 
Synovial B cells display heterogeneous subpopulations in RA synovium. a. scRNA-seq 
analysis identified naive B cells (SC-B1), memory B cells (SC-B2), autoimmune-associated 
B cells (ABCs) (SC-B3), and plasmablasts (SC-B4). Differential expression analysis is given 
by comparing leukocyte-rich RA (n = 16) with OA (n = 7) using bulk RNA-seq B cell 
samples. Effect size with 95% CI are given. b. Pathway enrichment analysis using 
immunologic gene sets indicates the distinct enriched pathways for each scRNA-seq cluster. 
Two-sided Kolmogorov-Smirnov test with 105 times permutation was performed; 
Benjamini-Hochberg was used to control the FDR of multiple tests. The standard names for 
the immunological gene sets from up to bottom are: Genes up-regulated in plasma cells 
versus memory B cells (GSE12366); Genes up-regulated in comparison of B cells versus 
plasmacytoid dendritic cells (pDC) (GSE29618); Genes up-regulated in B lymphocytes: 
naive versus plasmablasts (GSE42724); Genes up-regulated in B lymphocytes: human 
germinal center light zone versus dark zone (GSE38697); Genes up-regulated in comparison 
of memory IgM B cells versus plasma cells from bone marrow and blood (GSE22886); 
Genes up-regulated in comparison of memory IGG and IGA B cells versus plasma cells 
from bone marrow and blood (GSE22886). c. Detection of CD20+T-bet+CD11c+ (white 
arrow) in inflamed synovium by multicolor immunofluorescence. Immunofluorescent 
staining with antibodies CD20 (red), CD11c (white), T-bet (green), and counterstained with 
DAPI (blue). The experiment was repeated > 5 times with staining of 6 independent 
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leukocyte-rich RA samples with similar results. Image was acquired at 200 magnification. 
Scale bar is 50 μm. d-e. Identified subpopulations of B cells (n = 8,179) and disease status 
from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 8 OA by mass cytometry. f-g. Distinct 
expression patterns of protein markers by tSNE and averaged for each cluster in heatmap. h. 
Integrating mass cytometry clusters with bulk RNA-seq data using CCA shows that 
CD38+CD20−Ig− (plasmablasts) population is highly associated with gene expression of 
plasma cells makers, like XBP1. i. Integration of mass cytometry clusters with scRNA-seq 
clusters suggested that CD38++CD20−IgM+HLA-DR+ and CD38++CD20−IgM−IgD− are 
significantly associated with plasmablast (SC-B4); IgM−IgD−HLA-DR++CD20+CD11c+ B 
cells are associated with ABCs (SC-B3).
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Figure 8. 
Transcriptomic profiling of synovial cells reveals upregulation of inflammatory pathways in 
RA synovium. a. Pathway enrichment using bulk RNA-seq identified shared and unique 
inflammatory response pathways for each cell type. Two-sided Kolmogorov-Smirnov test 
with 105 permutations was performed on 18 leukocyte-rich RA, 17 leukocyte-poor RA, and 
14 OA. b. Bulk RNA-seq profiling of genes obtained from the significantly enriched 
pathways from (a) shows the averaged gene expression from each group (18 leukocyte-rich 
RA, 17 leukocyte-poor RA, and 14 OA) normalized across all cell type samples. c. scRNA-
seq profiling resolved that inflammatory cytokines/chemokines, interferon responsive, and 
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inflammatory responsive genes were driven by a global upregulation within a synovial cell 
type or discrete cell states.
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Table 1.
Connection between cell populations determined by mass cytometry and scRNA-seq clusters and disease 
associations. Bold mass cytometry clusters are significantly enriched in leukocyte-rich RA (one-sided 
Benjamini-Hochberg FDR q value < 0.05). Two significant digits are given to the one-sided F-tests conducted 
on nested models with MASC. 95% confidence interval (CI) for the odds ratio (OR) is given for each mass 
cytometry cluster. Where possible, we have identified the most similar scRNA-seq clusters for each cluster 
found by mass cytometry. The mass cytometry analysis is performed on downsampled datasets of 25,161 
fibroblasts from 23 patients, 15,298 monocytes from 26 patients, 19,985 T cells from 26 patients, and 8,179 B 
cells from 23 patients.
leukocyte-poor leukocyte-rich One-sided leukocyte-rich
scRNA-seq cluster mass cytometry cluster RA and OA RA MASC p value OR (CI)
THY1− Cadherin-11− 21% 4% 1.00 0.04 (0–0.2)
Lining (SC-F4) THY1− Cadherin-11+ 18% 2% 1.00 0.1 (0–0.3)
THY1− CD34+ HLA-DRhi 7% 3% 0.87 0.5 (0.3–1.2)
THY1− CD34− HLA-DRhi 17% 15% 0.48 1.2 (0.3–4.4)
HLAhi sublining (SC-F2) THY1+ CD34− HLA-DRhi 2% 36% 1.9×10−5 33.8 (11.7–113.1)
DKK3+ sublining (SC-F3) THY1+ CD34− HLA-DRlow 16% 15% 0.66 0.8 (0.3–1.8)
CD34+ sublining (SC-F1) THY1+ CD34+ HLA-DRlow 18% 4% 1.00 0.2 (0.1–0.4)
THY1+ CD34+ HLA-DRhi 2% 21% 1.6×10−4 25.5 (7.5–101.8)
NUPR1+ (SC-M2) CD11c− 30% 4% 1.00 0.1 (0–0.4)
IL1B+ (SC-M1), IFN-
activated (SC-M4)
CD11c+ CCR2+ 34% 40% 0.23 1.6 (0.7–3.6)
CD11c+ CD38− 13% 2% 1.00 0.1 (0–0.3)
CD11c+ CD38− CD64+ 13% 3% 0.93 0.3 (0.1–1)
IL1B+ (SC-M1), IFN-
activated (SC-M4),
C1QA+ (SC-M3)
CD11c+ CD38+ 15% 51% 6.7×10−5 7.8 (3.6–17.2)
CD4− CD8− 15% 9% 0.95 0.6 (0.3–1)
CCR7+(SC-T1) CD4+ CCR2+ 26% 13% 1.00 0.4 (0.2–0.7)
CD4+ HLA-DR+ 6% 2% 0.83 0.7 (0.2–4.1)
CD4+ PD-1+ ICOS− 13% 12% 0.81 0.9 (0.5–1.6)
Tph and Tfh (SC-T3) CD4+ PD-1+ ICOS+ 11% 25% 2.7×10−4 3.0 (1.7–5.2)
CD8+ PD-1− HLA-DR− 14% 9% 0.76 0.7 (0.3–1.5)
GZMK+GZMB+(SC-T6), 
GZMK+ (SC-T4),
CTLs (SC-T5)
CD8+ PD-1− HLA-DR+ 2% 1% 0.64 0.9 (0.4–2.2)
CD8+ PD-1+ HLA-DR− 13% 14% 0.40 1.1 (0.6–1.9)
Tph and Tfh (SC-T3) CD8+ PD-1+ HLA-DR+ 1% 15% 9.2×10−5 11.8 (4.9–34.2)
plasmablasts (SC-B4) CD38++ CD20− IgM− IgD− 6% 12% 0.01 3.3 (1.2–10.5)
CD38++ CD20− IgM+ HLA-
DR+
1% 3% 0.01 6.9 (1.3–83.1)
Memory B cells (SC-B2) IgM− IgD− HLA-DR− 27% 2% 1.00 0.1 (0–0.3)
Nat Immunol. Author manuscript; available in PMC 2019 November 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhang et al. Page 42
leukocyte-poor leukocyte-rich One-sided leukocyte-rich
scRNA-seq cluster mass cytometry cluster RA and OA RA MASC p value OR (CI)
CD38+ HLA-DR++ CD20− 
CD11c+
19% 6% 0.56 0.9 (0.1–6.7)
ABCs (SC-B3) IgM− IgD− HLA-DR++ CD20+ 
CD11c+
4% 12% 2.7×10−3 5.7 (1.8–22.3)
IgM− IgD− HLA-DR+ 32% 20% 0.98 0.4 (0.2–1)
IgA+ IgM− IgD− 5% 4% 0.68 0.9 (0.5–1.6)
Naïve B cells (SC-B1) IgM+ IgD− 22% 11% 0.97 0.5 (0.2–1)
IgM+ IgD+ CD11c− 12% 26% 0.02 4.0 (1.3–12.0)
IgM+ IgD+ CD11c+ 4% 7% 0.14 2.2 (0.74 – 7.7)
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